ipilimumab,nivolumab
bms
['nivo', 'cm914', ' ipi ']
the #oncoalerttoptweet #esmo22 day 3 tweet by our oncoalert colleague primary endpoint for phase 3 cm914 trial not met, nivo + ipi not superior to placebo--higher toxicity. no clear subgroups that benefit. best, 
?? Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees ?? We are #OncoAlert ??